Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Dihexa
Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
Dihexa is a synthetic hexapeptide analog of angiotensin IV developed by researchers at Washington State University. In animal models it demonstrated extraordinary potency for cognitive enhancement, reportedly 10 million times more potent than BDNF at promoting synaptogenesis. It is orally bioavailable, which is unusual for peptides. No human clinical trials have been conducted.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 1401708-83-5 |
| Molecular Formula | C21H41N3O4 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds hepatocyte growth factor (HGF) and potentiates its interaction with the c-Met receptor, dramatically amplifying HGF/c-Met signaling. This drives synaptogenesis, dendritic spine formation, and neuronal connectivity. Also inhibits insulin-regulated aminopeptidase (IRAP).
Dosing Research
No established human dosing. Underground protocols typically use 10-30 mg/day orally or 5-20 mg subcutaneously. Some users report sublingual administration. Given the lack of human pharmacokinetic data, all dosing is highly experimental.
Side Effects & Risks
No human safety data exists. Major theoretical concern is that potentiation of HGF/c-Met signaling is a known oncogenic pathway, raising significant cancer risk concerns. Other theoretical risks include excessive neuroplasticity, headache, and cardiovascular effects. This is considered one of the higher-risk underground peptides.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.